TY - JOUR
T1 - To Expand the Evidence Base About Harms from Tests and Treatments
AU - Korenstein, Deborah
AU - Harris, Russell
AU - Elshaug, Adam G.
AU - Ross, Joseph S.
AU - Morgan, Daniel J.
AU - Cooper, Richelle J.
AU - Cho, Hyung J.
AU - Segal, Jodi B.
N1 - Funding Information:
This project was not directly funded. DK’s work was supported in part by a grant from the National Cancer Institute to Memorial Sloan Kettering Cancer Center (P30 CA008748-50). JBS reports support from K24 AG049036-01A1 from the National Institute on Aging.
Funding Information:
DK reports that her spouse serves on the Scientific Advisory Boards of Vedanta Biosciences and Opentrons and does consulting work for Takeda. AGE holds the HCF Research Foundation Professorial Fellowship and has received direct income from providing low-value care-related data analytics and advice to the following: Australian state government health departments—Victoria, Queensland; Australian Dept of Veterans Affairs; Medibank Ltd.; Private Healthcare Australia (PHA); Australian Defence Force Joint Health Command. AGE receives direct income as a Ministerial appointee to the Australian Government Department of Health’s Medicare Benefits Schedule (MBS) Review Taskforce, as a Board Member of the New South Wales Bureau of Health Information, and as advisor to Cancer Australia. He is a member of the Expert Advisory Committee for Evidence-based Interventions (NICE, NHSCC, NHS Improvement and Academy of Medical Royal Colleges). In the past 36 months, JSR received research support through Yale University from Medtronic, Inc. and the Food and Drug Administration (FDA) to develop methods for postmarket surveillance of medical devices (U01FD004585), from the Centers of Medicare and Medicaid Services (CMS) to develop and maintain performance measures that are used for public reporting (HHSM-500-2013-13018I), and from the Blue Cross Blue Shield Association to better understand medical technology evaluation; Dr. Ross currently receives research support through Yale University from Johnson and Johnson to develop methods of clinical trial data sharing, from the Food and Drug Administration to establish Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI) program (U01FD005938), from the Medical Device Innovation Consortium as part of the National Evaluation System for Health Technology (NEST), from the Agency for Healthcare Research and Quality (R01HS022882), from the National Heart, Lung and Blood Institute of the National Institutes of Health (NIH) (R01HS025164, R01HL144644), and from the Laura and John Arnold Foundation to establish the Good Pharma Scorecard at Bioethics International and to establish the Collaboration for Research Integrity and Transparency (CRIT) at Yale. DJM reports funding from the National Institutes of Health, the Centers for Disease Control and Prevention, the Agency for Healthcare Research and Quality (AHRQ) and US Department of Veterans’ affairs (VA). RJC receives grant support from PCORI and from the American College of Emergency Physicians. Other authors report no potential conflicts of interest.
Funding Information:
The authors would like to thank the Lown Institute, which sponsored the meeting in 2019 on harms of overuse.
Publisher Copyright:
© 2021, Society of General Internal Medicine.
PY - 2021/7
Y1 - 2021/7
N2 - Rigorous evidence about the broad range of harms that might be experienced by a patient in the course of testing and treatment is sparse. We aimed to generate recommendations for how researchers might more comprehensively evaluate potential harms of healthcare interventions, to allow clinicians and patients to better include this evidence in clinical decision-making. We propose seven domains of harms of tests and treatments that are relevant to patients: (1) physical impairment, (2) psychological distress, (3) social disruption, (4) disruption in connection to healthcare, (5) labeling, (6) financial impact, and (7) treatment burden. These domains will include a range of severity of harms and variation in timing after testing or treatment, attributable to the service itself or a resulting care cascade. Although some new measures may be needed, diverse data and tools are available to allow the assessment of harms comprehensively across these domains. We encourage researchers to evaluate harms in sub-populations, since the harms experienced may differ importantly by demographics, social determinants, presence of comorbid illness, psychological state, and other characteristics. Regulators, funders, and editors might require either assessment or reporting of harms in each domain or require justification for inclusion and exclusion of different domains.
AB - Rigorous evidence about the broad range of harms that might be experienced by a patient in the course of testing and treatment is sparse. We aimed to generate recommendations for how researchers might more comprehensively evaluate potential harms of healthcare interventions, to allow clinicians and patients to better include this evidence in clinical decision-making. We propose seven domains of harms of tests and treatments that are relevant to patients: (1) physical impairment, (2) psychological distress, (3) social disruption, (4) disruption in connection to healthcare, (5) labeling, (6) financial impact, and (7) treatment burden. These domains will include a range of severity of harms and variation in timing after testing or treatment, attributable to the service itself or a resulting care cascade. Although some new measures may be needed, diverse data and tools are available to allow the assessment of harms comprehensively across these domains. We encourage researchers to evaluate harms in sub-populations, since the harms experienced may differ importantly by demographics, social determinants, presence of comorbid illness, psychological state, and other characteristics. Regulators, funders, and editors might require either assessment or reporting of harms in each domain or require justification for inclusion and exclusion of different domains.
UR - http://www.scopus.com/inward/record.url?scp=85099764658&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099764658&partnerID=8YFLogxK
U2 - 10.1007/s11606-021-06597-9
DO - 10.1007/s11606-021-06597-9
M3 - Editorial
C2 - 33479928
AN - SCOPUS:85099764658
SN - 0884-8734
VL - 36
SP - 2105
EP - 2110
JO - Journal of general internal medicine
JF - Journal of general internal medicine
IS - 7
ER -